Nyxoah SA develops and commercializes implantable neurostimulation systems for treating obstructive sleep apnea, a chronic sleep disorder affecting millions worldwide. The company's flagship product is a mild implantable device that stimulates the tongue muscle to maintain airway patency during sleep, targeting patients who are intolerant of or unsuitable for traditional therapies like continuous positive airway pressure. Nyxoah generates revenue primarily through device sales to hospitals and surgical centers at premium pricing, supplemented by procedure fees and ongoing patient management services, while building commercial operations across Europe, the United States, Australia, and Israel supported by clinical evidence generation to secure reimbursement coverage from public and private healthcare systems.